IFG Advisory LLC grew its holdings in Biogen Inc. (NASDAQ:BIIB – Free Report) by 786.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,637 shares of the biotechnology company’s stock after acquiring an additional 11,212 shares during the period. IFG Advisory LLC’s holdings in Biogen were worth $2,854,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds have also recently made changes to their positions in BIIB. BlackRock Inc. bought a new stake in Biogen during the 2nd quarter valued at approximately $3,453,878,000. Primecap Management Co. CA purchased a new position in Biogen in the 2nd quarter worth approximately $3,274,304,000. Wellington Management Group LLP lifted its holdings in Biogen by 5.3% in the 2nd quarter. Wellington Management Group LLP now owns 3,117,469 shares of the biotechnology company’s stock worth $673,560,000 after purchasing an additional 155,828 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in Biogen by 1,524.5% in the 3rd quarter. Russell Investments Group Ltd. now owns 2,175,055 shares of the biotechnology company’s stock worth $491,301,000 after purchasing an additional 2,041,161 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its holdings in Biogen by 139.4% in the 3rd quarter. Pictet Asset Management Holding SA now owns 2,039,056 shares of the biotechnology company’s stock worth $460,582,000 after purchasing an additional 1,187,237 shares in the last quarter. Institutional investors own 87.93% of the company’s stock.
Biogen Price Performance
Shares of BIIB opened at $253.40 on Monday. The company has a debt-to-equity ratio of 0.39, a current ratio of 1.95 and a quick ratio of 1.37. The stock has a market capitalization of $37.46 billion, a price-to-earnings ratio of 108.29, a price-to-earnings-growth ratio of 2.87 and a beta of 0.10. Biogen Inc. has a 1 year low of $160.36 and a 1 year high of $261.00. The business’s 50 day simple moving average is $233.35 and its 200-day simple moving average is $205.04.
Biogen (NASDAQ:BIIB – Get Free Report) last posted its earnings results on Wednesday, October 28th. The biotechnology company reported $2.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.99 by $0.63. Biogen had a net margin of 3.37% and a return on equity of 9.38%. The firm had revenue of $2.80 billion during the quarter, compared to analyst estimates of $2.63 billion. During the same period last year, the firm posted $4.81 earnings per share. Biogen’s revenue for the quarter was up 10.6% compared to the same quarter last year. As a group, equities analysts expect that Biogen Inc. will post 12.46 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on the company. BMO Capital Markets restated a “market perform” rating and issued a $220.00 price target on shares of Biogen in a research note on Monday, October 12th. Wolfe Research upgraded shares of Biogen from a “peer perform” rating to an “outperform” rating and set a $300.00 price objective on the stock in a research report on Thursday, August 13th. Barclays lifted their price objective on shares of Biogen from $200.00 to $230.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 28th. Guggenheim boosted their target price on shares of Biogen from $280.00 to $300.00 and gave the stock a “buy” rating in a report on Monday, November 2nd. Finally, Stifel Nicolaus set a $242.00 target price on shares of Biogen in a research report on Thursday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Biogen currently has an average rating of “Moderate Buy” and a consensus target price of $254.41.
Read Our Latest Stock Analysis on BIIB
Biogen Profile
Biogen is a biotechnology company focused on developing and commercializing medicines for neurological and rare diseases. Its areas of focus include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy and Friedreich’s ataxia. Its products include multiple sclerosis treatments such as Tysabri, Tecfidera and Vumerity, and Skyclarys for Friedreich’s ataxia. Biogen shares rights to several medicines with other companies, including Leqembi for Alzheimer’s disease with Eisai and Spinraza for spinal muscular atrophy with Ionis Pharmaceuticals.
Featured Articles
- Five stocks we like better than Biogen
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.
